SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/294163"
 

Search: onr:"swepub:oai:gup.ub.gu.se/294163" > Liver transcriptomi...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Baselli, G. A. (author)

Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker

  • Article/chapterEnglish2020

Publisher, publication year, extent ...

  • 2020-01-30
  • BMJ,2020

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/294163
  • https://gup.ub.gu.se/publication/294163URI
  • https://doi.org/10.1136/gutjnl-2019-319226DOI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Objective: Efforts to manage non-alcoholic fatty liver disease (NAFLD) are limited by the incomplete understanding of the pathogenic mechanisms and the absence of accurate non-invasive biomarkers. The aim of this study was to identify novel NAFLD therapeutic targets andbiomarkers by conducting liver transcriptomic analysis in patients stratified by the presence of the PNPLA3 I148M genetic risk variant. Design: We sequenced the hepatic transcriptome of 125 obese individuals. 'Severe NAFLD' was defined as the presence of steatohepatitis, NAFLD activity score ≥4 or fibrosis stage ≥2. The circulating levels of the most upregulated transcript, interleukin-32 (IL32), were measured by ELISA. Results: Carriage of the PNPLA3 I148M variant correlated with the two major components of hepatic transcriptome variability and broadly influenced gene expression. In patients with severe NAFLD, there was an upregulation of inflammatory and lipid metabolism pathways. IL32 was the most robustly upregulated gene in the severe NAFLD group (adjusted p=1×10-6), and its expression correlated with steatosis severity, both in I148M variant carriers and non-carriers. In 77 severely obese, and in a replication cohort of 160 individuals evaluated at the hepatology service, circulating IL32 levels were associated with both NAFLD and severe NAFLD independently of aminotransferases (p<0.01 for both). A linear combination of IL32-ALT-AST showed a better performance than ALT-AST alone in NAFLD diagnosis (area under the curve=0.92 vs 0.81, p=5×10-5). Conclusion: Hepatic IL32 is overexpressed in NAFLD, correlates with hepatic fat and liver damage, and is detectable in the circulation, where it is independently associated with the presence and severity of NAFLD. © 2020 American Medical Association. All rights reserved.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Dongiovanni, P. (author)
  • Rametta, R. (author)
  • Meroni, M. (author)
  • Pelusi, S. (author)
  • Maggioni, M. (author)
  • Badiali, S. (author)
  • Pingitore, P. (author)
  • Maurotti, S. (author)
  • Montalcini, T. (author)
  • Taliento, A. E. (author)
  • Prati, D. (author)
  • Rossi, G. (author)
  • Fracanzani, A. L. (author)
  • Mancina, Rosellina MargheritaGothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine(Swepub:gu)xmanro (author)
  • Romeo, Stefano,1976Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Wallenberg Laboratory(Swepub:gu)xroste (author)
  • Valenti, L. (author)
  • Göteborgs universitetInstitutionen för medicin, avdelningen för molekylär och klinisk medicin (creator_code:org_t)

Related titles

  • In:Gut: BMJ69, s. 1855-18660017-57491468-3288

Internet link

Find in a library

  • Gut (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view